Triple Agonist vs Single Agonist: A New Era
The comparison between retatrutide (triple agonist: GLP-1/GIP/glucagon) and Ozempic (semaglutide, single GLP-1 agonist) represents the evolution of incretin-based metabolic research from single-target to multi-target approaches. This guide examines the scientific differences.
What is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist approved for clinical use. It represents the current standard in single-receptor GLP-1 research.
Key Differences
| Feature | Retatrutide | Ozempic (Semaglutide) |
|---|---|---|
| Receptors | GLP-1 + GIP + Glucagon | GLP-1 only |
| Agonist type | Triple | Single |
| Development stage | Phase 2 completed | FDA approved |
| Dose range | 0.5-12mg weekly | 0.25-2.4mg weekly |
| GI side effects | Similar (dose-dependent) | Well-characterized |
The Glucagon Advantage
Retatrutide’s unique feature is glucagon receptor activation, which semaglutide lacks entirely. Glucagon increases hepatic fat oxidation, promotes thermogenesis, and enhances energy expenditure — mechanisms that complement the appetite-suppressing effects of GLP-1.
The GIP Component
The GIP receptor adds fat tissue-specific effects including enhanced lipid uptake and metabolism. This is the same mechanism that gives tirzepatide advantages over semaglutide alone.
Research Implications
Retatrutide’s phase 2 data showed the most impressive metabolic results of any incretin-based compound to date, suggesting that multi-receptor targeting may be the future of metabolic peptide research. However, semaglutide’s extensive clinical data and FDA approval provide a more comprehensive safety database.
For dosing details, see Retatrutide dosage guide and Semaglutide dosage chart.
For research purposes only. Visit COAs and catalog.